Head to head
Lanifibranor against Efruxifermin
An oral pan-PPAR agonist against an injected FGF21 analogue, in the same disease. Lanifibranor completed its 1,000 patient phase 3 dosing in September 2026 with results pending, which is the reason to read them side by side rather than to rank them.
Column A
LanifibranorLanifibranor, pan-PPAR agonist
An oral pan-PPAR agonist for MASH whose 1,000-patient Phase 3 (NATiV3) completed its last patient visit in September 2026, with results due by year end.
Column B
EfruxiferminEfruxifermin (EFX, AKR-001)
A weekly FGF21 analog that missed its 36-week primary endpoint in compensated MASH cirrhosis but improved fibrosis in 29% of patients by 96 weeks against 11% on placebo, with three Phase 3 SYNCHRONY trials under way.
Side by side, on the facts we can check
| Attribute | Lanifibranor | Efruxifermin |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; Phase 3 completed dosing | Investigational; Phase 3 |
| Half-life | Once-daily oral dosing | Weekly subcutaneous dosing |
| Molecular weight | 434.9 Da | 92,108 Da (Fc-FGF21 fusion protein) |
| Mechanism | Pan-PPAR agonism improving hepatic lipid metabolism, reducing inflammation and stellate-cell activation. | Long-acting FGF21 receptor agonism (FGFR1c/beta-klotho) that lowers liver fat, improves insulin sensitivity and reduces fibrosis. |
| Human studies cited | 2 | 2 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Lanifibranor and Efruxifermin?
Lanifibranor: An oral pan-PPAR agonist for MASH whose 1,000-patient Phase 3 (NATiV3) completed its last patient visit in September 2026, with results due by year end. Efruxifermin: A weekly FGF21 analog that missed its 36-week primary endpoint in compensated MASH cirrhosis but improved fibrosis in 29% of patients by 96 weeks against 11% on placebo, with three Phase 3 SYNCHRONY trials under way.
Which has stronger research evidence, Lanifibranor or Efruxifermin?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the Lanifibranor profile were human work, against 2 of 2 for Efruxifermin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Lanifibranor and Efruxifermin FDA-approved?
Lanifibranor: Investigational; Phase 3 completed dosing. Efruxifermin: Investigational; Phase 3.
Related posts
Blog articles that cover Lanifibranor or Efruxifermin, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.